Tim Wilsdon

Vice President

Mr. Tim Wilsdon is a vice president in CRA’s Life Sciences Practice in London, England and is responsible for leading the policy sector in the global Life Sciences Practice.

He commonly talks at international conferences on issues to do with health technology assessment and pricing and reimbursement and the economics of innovation for pharmaceutical products and diagnostics. He has also acted as an expert in international arbitrations involving multinational pharmaceutical companies and was EFPIA and PhRMA’s economic expert during the DG Competition’s Sector Inquiry.

Mr. Wilsdon has completed studies for the European Commission (including DG GROW and TRADE) and the pharmaceutical industry (through EFPIA, PhRMA, and country associations such as Innovative Medicines Canada, ABPI, LIF, and IPASA) on how healthcare markets could be reformed for efficiency. He was responsible for leading an assignment for the European Commission determining whether there was a global crisis in innovation and the risks of importation. For the industry, he has undertaken assessments of health technology assessments, international reference pricing, early access agreements, managed entry agreements and many other issues.

Selected engagements

  • 01
    Adapting ICER to transformative medicines
    Our client is a global pharma company and is interested to understand the implications of the 2019/2020 updates to the ICER Value Assessment Framework...
    View engagement
  • 02
    Assessed likely policy response in major markets to COVID-19
    Identified risks to pricing and market access in global markets for related and non-related therapeutic areas CRA Approach Developed a framework that captures...
    View engagement
  • 03
    Characterising the benefits of personalised medicines
    Our client was seeking to develop an evidence base to support the contribution of personalised medicines to patients, healthcare systems and society more...
    View engagement